Sirona Biochem

(SBM:TSXV)

Developer for Pharmaceutical & Cosmetic Marketplaces

Sirona Biochem (SBM:TSXV) is not a traditional biotech company. Sirona is a product – pipeline company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds’ efficacy and safety. Sirona Biochem’s compounds are being developed for both pharmaceutical and cosmetic marketplaces and are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem’s wholly-owned French laboratory is a recipient of multiple French national scientific awards and a European Union and French government grant.

Developing
Pharmaceutical & Cosmetic Compounds

Sirona Biochem was founded in 2009 by its current Chairman and CEO, Dr. Howard Verrico. The Company’s first transaction was to acquire an exclusive global license to TFChem’s proprietary diabetes drug, the SGLT2 Inhibitor.

In 2011, Sirona Biochem went on to acquire TFChem’s entire platform and development laboratory in Rouen, France. As a result of the transaction, the founder of TFChem, Dr. Geraldine Deliencourt-Godefroy, became the largest shareholder and Chief Scientific Officer of Sirona Biochem.

Sirona Biochem is a biotechnology company with an innovative platform technology of fluorination chemistry developed by our subsidiary, research and development laboratory TFChem. The platform is used to develop safer, more effective cosmetic and pharmaceutical active ingredients which are licensed to partners in exchange for upfront, milestone and royalty payments.

Recent News

OFFICIAL STOCK INFO

Schedule a time with Momentum to discuss further

TOP
Message Us
Loading...